Smartkem board approves 1-for-50 reverse stock split
Smartkem's board approved a 1-for-50 reverse split to satisfy Nasdaq's minimum bid price requirement. The split becomes effective August 20, 2026, and will reduce the trading float…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Smartkem's board approved a 1-for-50 reverse split to satisfy Nasdaq's minimum bid price requirement. The split becomes effective August 20, 2026, and will reduce the trading float…
BMO 2026-C15 Mortgage Trust filed a Current Report on Form 8-K with the SEC to satisfy periodic reporting requirements. No material financial information or developments were discl…
FDA issued a discussion paper seeking public input on the regulation of generative AI-enabled medical devices, covering risk assessment, premarket evaluation, and postmarket monito…
DriveItAway Holdings will voluntarily terminate its registration under the Exchange Act to reduce costs, shifting its reporting obligations to the OTC Markets Alternative Reporting…
ASP Isotopes subsidiary Quantum Leap Energy is initiating a pilot-scale metal conversion facility in Namibia to evaluate nuclear fuel cycle processes, driven by the global demand f…
Amylyx announced positive results from a Phase 3 trial of avexitide for post-bariatric hypoglycemia, showing a statistically significant reduction in severe hypoglycemic events. Th…
Flotek paused operations on its Puerto Rico power project after the Oversight Board directed PREPA to terminate the contract. The 10-year agreement's future is uncertain, though th…
Adia Nutrition, Inc. filed an amendment to its Articles of Incorporation to change its name from Adia Med, Inc. changing its corporate identity to Adia Nutrition, Inc.
Independent valuation advisor Altus Group U.S. Inc. consented to its named reference in the Company's Form 8-K and related filings, confirming its role in the valuation process for…
The company filed this filing as consent from Altus Group regarding their role in the valuation process. The stock closed at $20.63 per share Monday, a gain of 0.05%.
TIAA Real Estate Account filed an Exhibit 99.1 adding updated 'Frequently Asked Questions' as of June 30, 2026. This regulatory filing details policies regarding investment strateg…
Cullen/Frost issued a forward-looking statement detailing the potential adverse effects of recent military conflict between the US and Iran on global markets, oil prices, inflation…
EyePoint reported mixed results from its LUGANO Phase 3 trial for wet AMD drug DURAVYU, missing the primary endpoint due to a small patient cohort but excelling in key secondary me…
NOAA published a notice to prepare an Environmental Impact Statement for The Metals Company, Inc.'s USA-B application area in the Pacific Ocean, a key regulatory milestone.
Vital Farms, Inc. has filed an Amended and Restated Bylaws document, detailed in an 8-K filing. This update standardizes the corporation's internal governance framework and policie…
The FDA issued an Emergency Use Authorization for Simparica TRIO to treat New World screwworm infestations in dogs and puppies.
Palisade Bio secured FDA clearance to advance its Phase 2 ASCENTRA trials for the IBD treatment PALI-2108, showcasing strong clinical data from its first study. This progression hi…
National Health Investors Inc filed a Q2 2026 supplemental financial filing, which contains forward-looking statements and non-GAAP financial measures related to its financial posi…
CervoMed received Innovation Passport Designation for neflamapimod in dementia with Lewy bodies; additionally, Q2 financial results and updates for both DLB and nonfluent variant p…
Latigo Biotherapeutics, Inc. amended its Certificate of Incorporation under Delaware law. The company increased its authorized Common Stock to 999,999,999 shares.